NOTE 9 — NET LOSS PER SHARE
Basic and diluted net loss per common share for the three and six months ended June 30, 2016 and 2015 was determined by dividing net loss by the weighted average common shares outstanding d uring the period. The Company’s potentially dilutive shares, which include 1,399,787 stock options, 14,000 unvested common shares, and 19,600 warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be antidilutive.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Dipexium Pharmaceuticals, Inc. makes a similar move, sign up!
Other recent filings from the company include the following:
Regulation FD - Jan. 8, 2018